EGFR and breast cancer: For other biomarkers investigated (IL6, CTLA4, TGFβ, PDGFRα, PDGFR β, EGFR and VEGF) a larger sample size would be required to better verify their reliability as prognostic biomarkers in patients affected by BC and SSc.